Ruplizumab

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameRuplizumab
Drug Alias NameAntovahu5c8T-BAM5c8BG 9588 +[15] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionCD40 ligand inhibitors
TargetsCD40 ligand
Therapy Area/IndicationsRejection of renal transplantationAutoimmune DiseasesLupus Erythematosus, Systemic +[8] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesBiogen Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesBiogen IncNational Institute Of Arthritis And Musculoskeletal And Skin DiseasesNational Institute Of Diabetes And Digestive And Kidney Diseases
Active IndicationsN/A
Inactive IndicationsRejection of renal transplantationAutoimmune DiseasesLupus Erythematosus, Systemic +[8] 

Other Information

ATC CodeN/A
Related LinksWikipediaDrugBankKEGG